Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients
AbstractLipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared not to be effective enough. Homozygous familial hypercholesterolemia represents a clear indication to start LA therapy. Another recognized indication is a severe hypercholesterolemia, which induced CVE, often in association with other risk factors. In the last years, an expressive elevation of lipoprotein(a) (Lp(a)) emerged as an indication for LA. In Germany, progress of atherosclerosis should have been documented before the permission to start LA therapy is given in these patients. Usually, all LA methods acutely decrease both LDL-C and Lp(a). However, specific columns which reduce only Lp(a) are available. Case reports and prospective observations comparing the situation before and during LA therapy clearly show a high efficiency with respect to the reduction of CVE, especially in patients with high Lp(a) levels. PCSK9 inhibitors may reduce the need for LA in patients with heterozygous or polygenetic hypercholesterolemia, but in some patients, a combination of these drugs with LA will be necessary. In the future, an antisense oligonucleotide against apolipoprotein(a) may offer an alternative therapeutic approach. View Full-Text
Share & Cite This Article
Julius, U. Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. J. Cardiovasc. Dev. Dis. 2018, 5, 27.
Julius U. Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients. Journal of Cardiovascular Development and Disease. 2018; 5(2):27.Chicago/Turabian Style
Julius, Ulrich. 2018. "Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients." J. Cardiovasc. Dev. Dis. 5, no. 2: 27.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.